Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux‐en‐Y gastric bypass. A double‐blinded, randomized trial

• Published in: Clinical endocrinology (Oxford) 2018-12, Vol.89 (6), p.734-741
• Main Authors: Ring Madsen, Lene, Espersen, Rasmus, Rejnmark, Lars, Richelsen, Bjørn
• Format: Article
• Language: English
• Subjects: 25-Hydroxyvitamin D; Alkaline phosphatase; bariatric surgery; bone remodelling; Bone turnover; Calcium absorption; Calcium carbonate; Citric acid; Collagen (type I); dietary supplements; Gastric bypass; hyperparathyroidism; Obesity; Osteocalcin; Parathyroid; Parathyroid hormone; Patients; Plasma levels; Procollagen; Supplements; Vitamin D
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/cen.13836

Summary Objective Following Roux‐en‐Y gastric bypass (RYGB), elevated parathyroid hormone (PTH) levels potentially harmful to bone health are commonly observed. Owing to assumed superior absorption, calcium citrate is often recommended over calcium carbonate following RYGB for the treatment of elevated PTH. We aimed to investigate the impact of either calcium carbonate or calcium citrate (1200 mg elementary calcium) in patients with elevated PTH levels following RYGB. Design Clinical, double‐blinded, randomized controlled trial of a 12‐week duration at a Danish University Hospital. Patients and Measurements Thirty‐nine (no drop out) RYGB operated patients with elevated PTH levels (PTH > 6.9 pmol/L) and normal plasma levels of calcium and 25‐hydroxyvitamin D were randomized to either calcium carbonate or calcium citrate (1200 mg elementary calcium/daily). We assessed change in PTH as the primary outcome. Results The effect of the two calcium formulations on change in PTH was comparable and neutral: −1.9% (calcium citrate) vs +0.9% (calcium carbonate), P = 0.680. Compared to the carbonate‐treated group, the following bone turnover markers decreased significantly in the citrate‐treated group: procollagen I N‐terminal propeptide (−16.6% vs −3.2%, P = 0.021), osteocalcin (−17.2% vs −4.3%, P = 0.007) and bone‐specific alkaline phosphatase (−5.9% vs 3.7%, P = 0.027) and remained significantly decreased after multivariable adjustment. Conclusion Increasing the dose of calcium supplementation in RYGB operated patients with slightly elevated PTH levels does not normalize PTH levels, regardless of the type of supplement. Our results do not support recommending supplementation with calcium citrate over calcium carbonate in RYGB patients.